Chordia Therapeutics,Inc Logo

Chordia Therapeutics,Inc

Developing first-in-class, small-molecule anti-cancer drugs targeting RNA deregulation.

190A | T

Overview

Corporate Details

ISIN(s):
JP3283730004
LEI:
Country:
Japan
Address:
藤沢市村岡東2−26−1
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

Chordia Therapeutics Inc. is a clinical-stage biotechnology company specializing in the research and development of innovative, first-in-class anti-cancer drugs. Established in November 2017 as a spin-out from a major pharmaceutical company, its mission is to deliver novel treatments to patients with unmet medical needs. The company focuses on developing a pipeline of small-molecule drug candidates that target RNA deregulation stress, a key factor in cancer development. Chordia Therapeutics operates with a focused R&D model, outsourcing activities such as manufacturing, distribution, and sales to external partners to advance its therapeutic programs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-21 05:00
Registration Form
確認書
Japanese 8.1 KB
2025-11-21 05:00
Annual Report
有価証券報告書-第8期(2024/09/01-2025/08/31)
Japanese 2.6 MB
2025-09-05 08:30
Registration Form
有価証券届出書(参照方式)
Japanese 534.8 KB
2025-05-16 02:45
Major Shareholding Notification
臨時報告書
Japanese 20.2 KB
2025-04-11 04:50
Interim Report
半期報告書-第8期(2024/09/01-2025/08/31)
Japanese 144.4 KB
2025-04-11 04:50
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-12-17 07:30
Registration Form
訂正確認書
Japanese 8.7 KB
2024-11-29 07:37
Post-Annual General Meeting Information
臨時報告書
Japanese 23.1 KB
2024-11-29 07:36
Registration Form
確認書
Japanese 8.1 KB
2024-11-29 07:35
Governance Information
内部統制報告書-第7期(2023/09/01-2024/08/31)
Japanese 21.2 KB
2024-11-29 07:34
Annual Report
有価証券報告書-第7期(2023/09/01-2024/08/31)
Japanese 2.8 MB
2024-07-16 06:55
Quarterly Report
四半期報告書-第7期第3四半期(2024/03/01-2024/05/31)
Japanese 123.4 KB
2024-07-16 06:55
Report Publication Announcement
確認書
Japanese 8.0 KB
2024-06-06 08:00
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 2.9 MB
2024-05-29 04:00
Registration Form
訂正有価証券届出書(新規公開時)
Japanese 2.9 MB

Automate Your Workflow. Get a real-time feed of all Chordia Therapeutics,Inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chordia Therapeutics,Inc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Chordia Therapeutics,Inc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Material Group inc. Logo
A professional services firm offering PR consulting, marketing, and brand strategy.
Japan
156A
Medesis Pharma S.A. Logo
Develops therapies for CNS disorders and radiation exposure via a drug delivery platform.
France
ALMDP
Medicofarma Biotech Spolka Akcyjna Logo
A biotech R&D company developing innovative drugs and devices with a focus on oncology therapies.
Poland
MDB
Medpace Holdings, Inc. Logo
Global CRO providing full-service clinical development to biotech, pharma & medical device industries.
United States of America
MEDP
Develops biomarker-based precision therapies for oncology and other incurable diseases.
South Korea
235980
Medrx Co.,Ltd. Logo
Develops and licenses transdermal drug delivery systems for the pharmaceutical industry.
Japan
4586
Developing nanomedicines and drug delivery systems for oncology, hematology, and diagnostics.
Malaysia
N/A
A holding company driving regional growth by supporting construction, HR, and nursing care businesses.
Japan
7369
Mendus Logo
Developing immunotherapies using dendritic cells to prevent cancer recurrence and improve survival.
Sweden
IMMU
Develops AI-driven, glasses-free 3D holographic displays for the defense sector.
United States of America
M3D

Talk to a Data Expert

Have a question? We'll get back to you promptly.